Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?
Eberle
Alex N
AN
University Hospital Basel, Switzerland. alex-n.eberle@unibas.ch
Beglinger
Christoph
C
D004701:Endocrine Gland Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D017567:Karnofsky Performance Status; D008279:Magnetic Resonance Imaging; D015282:Octreotide / Q000031:analogs & derivatives; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C447941:lutetium Lu 177 dotatate; D015282:Octreotide